Cocrystal Pharma presented data on its oral protease inhibitor, CDI-988, at the 39th International Conference on Antiviral Research (ICAR 2026). The company has completed enrollment for the stage 1 infectivity cohort of its Phase 1b human challenge study. CDI-988 is being developed as both a preventive and treatment for norovirus, which currently has no approved vaccines or therapies. The drug has received FDA Fast Track designation. Phase 1 results showed the drug was safe and well-tolerated at doses up to 1,200 mg.